The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function
NCT ID: NCT00627068
Last Updated: 2011-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2007-07-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease
NCT00013975
Precursors of CVD Risk Factors--Project Heartbeat
NCT00005478
Biochemical and Genetic Markers of Hypertension in Women
NCT00090467
Inflammatory Genomics in Human Carotid Artery Disease
NCT00070668
Genetic Predictors of Incident Cardiovascular Disease
NCT00035672
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. High and low cardiovascular risk subjects will be identified based on age or history of cardiovascular disease. Endothelial function will be measured by ultrasound.
2. EPCs will be isolated from peripheral blood of these subjects. EPC function will be assessed by measuring adhesion to endothelium, migration, proliferation, and differentiation, and compared to their expression and activity of eNOS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
High cardiovascular risk age over 61 years.
No interventions assigned to this group
2
Low Cardiovascular risk age over 61.
No interventions assigned to this group
3
High cardiovascular risk age over 25 but under 61.
No interventions assigned to this group
4
Low cardiovascular risk age over 25 under 61.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult of 18 years or older
* Subjects willing to provide blood and tissue samples
Exclusion Criteria
* Those unable to consent for themselves.
* Those who cannot read English.
* Patients on Viagra, Levitra, or Cialis
* Patients with malignant disease
* Patients with hematological abnormalities
* Patients with fevers of unknown origin
* Severe comorbidity or alcohol/drug dependence
* Women who are post-menopausal and on hormone replacement therapy, or premenopausal and on birth control pills (premenopausal women will be screened verbally and then by assay of LH and FSH levels in blood samples to identify women in the follicular phase of their menstrual cycle, to reduce variability)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yerem Yeghiazarians
Assistant Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yerem Yeghiazarians, M.D
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSF, Department of Cardiology
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HL086917
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.